Zenas BioPharma Announces Positive Results from Phase 2 MoonStone Trial
Zenas BioPharma, a clinical-stage global biopharmaceutical company, announced positive results from the Phase 2 MoonStone trial of obexelimab in Relapsing Multiple Sclerosis (RMS).
Obexelimab met its primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhancing T1 lesions compared with placebo, p=0.0009.
Obexelimab met primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhancing T1 lesions compared with placebo, p=0.0009
Zenas BioPharma is committed to developing transformative therapies for patients with autoimmune diseases.
Author's summary: Zenas BioPharma reports positive trial results.
More News
- iOS 26.1 Coming Soon: New Features for Your iPhone and Release Date
- Giving States Waivers From Accountability Is a Dangerous Step Backward for Kids
- Senate questions P8 billion farm-to-market roads in DPWH budget
- MMJ BioPharma Cultivation: EXPOSÉ: DEA's Marijuana Licensing Scheme Exposed - MMJ BioPharma's Case Reveals DEA Contradiction Blocking FDA Approved Cannabis Medicine
- Deandre Ayton claims Los Angeles Lakers superstars ‘troll him’ to get him going
- The new age of pediatric medication awareness - Express Healthcare
- Elon Musk could step down if Tesla pay plan is rejected
- Meralco profit jumps 14% to P40 billion in 9 months
- Bank of Canada expected to cut interest rate this week as forecasters see more weakness to come for economy
- D&H Distributing’s Advanced Solutions Plus Unit To Focus On The Enterprise, ‘A Pivotal Evolution’ For Its Business